Adamas Pharmaceuticals Stock Forecast, Price & News

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Adamas Pharmaceuticals stock.
View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Adamas Pharmaceuticals?

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Adamas Pharmaceuticals.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its quarterly earnings results on Sunday, August, 8th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.02.
View Adamas Pharmaceuticals' earnings history.

How has Adamas Pharmaceuticals' stock been impacted by COVID-19?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADMS shares have increased by 69.2% and is now trading at $5.16.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ADMS?

4 brokerages have issued twelve-month price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $6.00 to $12.50. On average, they expect Adamas Pharmaceuticals' share price to reach $9.50 in the next year. This suggests a possible upside of 84.1% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:

• Neil F. McFarlane, Chief Executive Officer & Director
• Christopher B. Prentiss, Chief Financial Officer (LinkedIn Profile)
• Adrian Quartel, Chief Medical Officer
• Vijay Shreedhar, Chief Commercial Officer (LinkedIn Profile)
• Jill M. Jene, Head-Corporate Development & Strategy

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Adamas Pharmaceuticals' key competitors?

Some companies that are related to Adamas Pharmaceuticals include Janux Therapeutics (JANX), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Nkarta (NKTX), Dyne Therapeutics (DYN), ORIC Pharmaceuticals (ORIC), Avidity Biosciences (RNA), Protagonist Therapeutics (PTGX), Omeros (OMER), Zogenix (ZGNX), Celularity (CELU), BioXcel Therapeutics (BTAI), Edgewise Therapeutics (EWTX), ADVANZ PHARMA (CXRXF) and Phibro Animal Health (PAHC).
View all of ADMS's competitors.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.56%), AIGH Capital Management LLC (5.34%), Point72 Asset Management L.P. (4.94%), Vanguard Group Inc. (3.84%), Renaissance Technologies LLC (1.72%) and BlackRock Inc. (1.65%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Martha J Demski, Spyridon Papapetropoulos and Vijay Shreedhar.
View institutional ownership trends for Adamas Pharmaceuticals.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Susquehanna International Group LLP, Squarepoint Ops LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Deutsche Bank AG, and DCF Advisers LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Martha J Demski, and Vijay Shreedhar.
View insider buying and selling activity for Adamas Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., MAI Capital Management, AIGH Capital Management LLC, FMR LLC, BlackRock Inc., State Street Corp, Bridgeway Capital Management LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Adamas Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $5.16.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $235.28 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 138 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Where are Adamas Pharmaceuticals' headquarters?

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at (510) 450-3500 or via email at [email protected].